Literature DB >> 12425742

Design principles of liquid nebulization devices currently in use.

Joseph L Rau1.   

Abstract

Liquid nebulization is a common method of medical aerosol generation. Nebulizers are of 2 types: jet (or pneumatic) small-volume nebulizer, and ultrasonic nebulizer. Jet nebulizers are based on the venturi principle, whereas ultrasonic nebulizers use the converse piezoelectric effect to convert alternating current to high-frequency acoustic energy. Important variables for both types of nebulizer are treatment time required, particle size produced, and aerosol drug output. There are several advantages to jet nebulization, including that effective use requires only simple, tidal breathing, and that dose modification and dose compounding are possible. Disadvantages include the length of treatment time and equipment size. Design modifications to the constant-output nebulizer have resulted in breath-enhanced, open-vent nebulizers such as the Pari LC Plus and the dosimetric AeroEclipse. Ultrasonic nebulizers generally have a higher output rate than jet nebulizers, but a larger average particle size. Ultrasonic nebulizers can also substantially increase reservoir solution temperature, the opposite of jet nebulizer cooling. Drug concentration in the reservoir does not increase with ultrasonic nebulization, as it does with jet nebulization. Ultrasonic nebulizers have the same advantages as jet nebulizers. Ultrasonic nebulizers are more expensive and fragile than jet nebulizers, may cause drug degradation, and do not nebulize suspensions well. Neither type of nebulizer meets the criteria for an ideal inhaler: efficient and quick dose delivery with reproducibility, cost-effectiveness, and no ambient contamination by lost aerosol.

Mesh:

Substances:

Year:  2002        PMID: 12425742

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  7 in total

1.  Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

2.  Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.

Authors:  Elke Kleemann; Thomas Schmehl; Tobias Gessler; Udo Bakowsky; Thomas Kissel; Werner Seeger
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

Review 3.  In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Lucy E A Hardaker; Ross H M Hatley
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

Review 4.  siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?

Authors:  Aditi Mehta; Thomas Michler; Olivia M Merkel
Journal:  Adv Healthc Mater       Date:  2021-01-27       Impact factor: 11.092

Review 5.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

6.  Inhaled vitamin A is more effective than intramuscular dosing in mitigating hyperoxia-induced lung injury in a neonatal rat model of bronchopulmonary dysplasia.

Authors:  Craig A Gelfand; Reiko Sakurai; Ying Wang; Yitian Liu; Robert Segal; Virender K Rehan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 6.011

7.  Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy.

Authors:  Juliane Nguyen; Terry W J Steele; Olivia Merkel; Regina Reul; Thomas Kissel
Journal:  J Control Release       Date:  2008-06-19       Impact factor: 9.776

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.